{"created":"2023-06-19T11:23:01.802991+00:00","id":1278,"links":{},"metadata":{"_buckets":{"deposit":"775b20e6-c2da-4808-960d-ab615470a281"},"_deposit":{"created_by":12,"id":"1278","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"1278"},"status":"published"},"_oai":{"id":"oai:jichi-ir.repo.nii.ac.jp:00001278","sets":["14:46"]},"author_link":[],"item_2_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-03","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"48","bibliographicPageStart":"43","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"自治医科大学紀要"},{"bibliographic_title":"Jichi Medical University Journal","bibliographic_titleLang":"en"}]}]},"item_2_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"　転移性ホルモン感受性前立腺癌に対する，upfront docetaxel化学療法の全生存期間（overall survival ：OS）延長が過去の報告で示されている。当院におけるupfront docetaxel化学療法とcombined androgen blockade（CAB）療法の，OS，無増悪生存期間（progression free survival：PFS1）および，２次と３次後療法を含めたPFS2，PFS3と有害事象に関して検討した。OSとPFS1に有意差は認めず（p=0.28，p=0.068），PFS2とPFS3はいずれも化学療法群で有意に延長した（p=0.0062，p=0.012）。化学療法群においてGrade 3以上の好中球減少症を62%認めるも，発熱性好中球減少症の発症はなく，比較的安全に71%の患者で化学療法を６コース完遂できた。","subitem_description_type":"Abstract"}]},"item_2_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"names":[{"name":"Yokoyama, Hirotaka","nameLang":"en"}]},{"names":[{"name":"Kameda, Tomohiro","nameLang":"en"}]},{"names":[{"name":"Sugihara, Toru","nameLang":"en"}]},{"names":[{"name":"Yanase, Atsushi","nameLang":"en"}]},{"names":[{"name":"Watanabe, Risako","nameLang":"en"}]},{"names":[{"name":"Akimoto, Takahiro","nameLang":"en"}]},{"names":[{"name":"Kamei, Jun","nameLang":"en"}]},{"names":[{"name":"Kubo, Taro","nameLang":"en"}]},{"names":[{"name":"Ando, Satoshi","nameLang":"en"}]},{"names":[{"name":"Fujimura, Tetsuya","nameLang":"en"}]}]},"item_2_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"自治医科大学"}]},"item_2_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1881-252X","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"横山, 博崇","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"亀田, 智弘","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"杉原, 亨","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"梁瀬, 敦史","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"渡邉, 梨紗子","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"秋元, 隆宏","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"亀井, 潤","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"久保, 太郎","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"安東, 聡","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"藤村, 哲也","creatorNameLang":"ja"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-06-09"}],"displaytype":"detail","filename":"自治医科大学紀要 1881-252X(45)P43-48 2023.pdf","filesize":[{"value":"344.8 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"自治医科大学紀要 1881-252X(45)P43-48 2023","url":"https://jichi-ir.repo.nii.ac.jp/record/1278/files/自治医科大学紀要 1881-252X(45)P43-48 2023.pdf"},"version_id":"959ea0f3-3f94-44d9-8b3f-373ae0e0b0e4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"転移性ホルモン感受性前立腺癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"upfront docetaxel化学療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"combined androgen blockade療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"転移性ホルモン感受性前立腺癌に対するupfront docetaxel化学療法とcombined androgen blockade療法の治療成績","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"転移性ホルモン感受性前立腺癌に対するupfront docetaxel化学療法とcombined androgen blockade療法の治療成績","subitem_title_language":"ja"},{"subitem_title":"Outcome of upfront docetaxel chemotherapy and combined androgen blockade therapy for metastatic hormone-sensitive prostate cancer","subitem_title_language":"en"}]},"item_type_id":"2","owner":"12","path":["46"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-06-09"},"publish_date":"2023-06-09","publish_status":"0","recid":"1278","relation_version_is_last":true,"title":["転移性ホルモン感受性前立腺癌に対するupfront docetaxel化学療法とcombined androgen blockade療法の治療成績"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-08-25T06:00:35.720253+00:00"}